Literature DB >> 31471400

Quality Indicators and Survival Outcome in Stage IIIB-IVB Epithelial Ovarian Cancer Treated at a Single Institution.

Inga Steinberga1, Kjell Jansson2, Bengt Sorbe3.   

Abstract

BACKGROUND/AIM: To investigate the overall survival rate, quality indicators and treatment outcome in FIGO stage IIIB-IVB epithelial ovarian cancer at a University Hospital in Sweden between 2006 and 2015.
MATERIALS AND METHODS: A cohort of 110 patients was followed-up for 3-12 years after cancer diagnosis. Three main groups (primary surgery, neoadjuvant chemotherapy, palliative treatment), and six subgroups were defined according to treatment modality.
RESULTS: The mean age was 65 years. Patients were observed for a mean of 50 months. The total resection frequency was 83%. Significant differences in overall survival at 5 years were observed between the groups varying from 60% to 12%.
CONCLUSION: Patient age, tumor stage and complete tumor removal at surgery were significant, independent prognostic factors of overall survival. Complication rate was a significant adverse prognostic factor in univariate analysis. Data discrepancy was observed between public quality reports and locally obtained data. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Epithelial ovarian cancer; quality factors; surgical treatment; survival

Mesh:

Year:  2019        PMID: 31471400      PMCID: PMC6755028          DOI: 10.21873/invivo.11632

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  31 in total

Review 1.  Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.

Authors:  Kenneth Jaaback; Nick Johnson; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

2.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

Authors:  Sean Kehoe; Jane Hook; Matthew Nankivell; Gordon C Jayson; Henry Kitchener; Tito Lopes; David Luesley; Timothy Perren; Selina Bannoo; Monica Mascarenhas; Stephen Dobbs; Sharadah Essapen; Jeremy Twigg; Jonathan Herod; Glenn McCluggage; Mahesh Parmar; Ann-Marie Swart
Journal:  Lancet       Date:  2015-05-19       Impact factor: 79.321

3.  Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.

Authors:  Takashi Onda; Toyomi Satoh; Toshiaki Saito; Takahiro Kasamatsu; Toru Nakanishi; Kenichi Nakamura; Masashi Wakabayashi; Kazuhiro Takehara; Motoaki Saito; Kimio Ushijima; Hiroaki Kobayashi; Kei Kawana; Harushige Yokota; Masashi Takano; Nobuhiro Takeshima; Yoh Watanabe; Nobuo Yaegashi; Ikuo Konishi; Toshiharu Kamura; Hiroyuki Yoshikawa
Journal:  Eur J Cancer       Date:  2016-06-17       Impact factor: 9.162

Review 4.  Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.

Authors:  Helen J Mackay; Mark F Brady; Amit M Oza; Alexander Reuss; Eric Pujade-Lauraine; Ann M Swart; Nadeem Siddiqui; Nicoletta Colombo; Michael A Bookman; Jacobus Pfisterer; Andreas du Bois
Journal:  Int J Gynecol Cancer       Date:  2010-08       Impact factor: 3.437

5.  Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

Authors:  Robert E Bristow; Rafael S Tomacruz; Deborah K Armstrong; Edward L Trimble; F J Montz
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

6.  Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.

Authors:  Dennis S Chi; Eric L Eisenhauer; Oliver Zivanovic; Yukio Sonoda; Nadeem R Abu-Rustum; Douglas A Levine; Matthew W Guile; Robert E Bristow; Carol Aghajanian; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2009-04-23       Impact factor: 5.482

7.  Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials.

Authors:  S Mahner; C Eulenburg; A Staehle; K Wegscheider; A Reuss; E Pujade-Lauraine; P Harter; I Ray-Coquard; J Pfisterer; A du Bois
Journal:  Eur J Cancer       Date:  2012-08-23       Impact factor: 9.162

8.  Compliance to consensus recommendations, surgeon's experience, and introduction of a quality assurance and management program: influence on therapy of early-stage ovarian carcinoma.

Authors:  Stefan Kommoss; Philipp Harter; Alexander Traut; Deivis Strutas; Nina Riegler; Christine Buhrmann; Ruth Gomez; Andreas du Bois
Journal:  Int J Gynecol Cancer       Date:  2009-05       Impact factor: 3.437

9.  Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.

Authors:  Brandon-Luke L Seagle; Stephen Graves; Anna E Strohl; Shohreh Shahabi
Journal:  Int J Gynecol Cancer       Date:  2017-10       Impact factor: 3.437

10.  Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

Authors:  Willemien J van Driel; Simone N Koole; Karolina Sikorska; Jules H Schagen van Leeuwen; Henk W R Schreuder; Ralph H M Hermans; Ignace H J T de Hingh; Jacobus van der Velden; Henriëtte J Arts; Leon F A G Massuger; Arend G J Aalbers; Victor J Verwaal; Jacobien M Kieffer; Koen K Van de Vijver; Harm van Tinteren; Neil K Aaronson; Gabe S Sonke
Journal:  N Engl J Med       Date:  2018-01-18       Impact factor: 91.245

View more
  2 in total

1.  Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands.

Authors:  G M Nieuwenhuyzen-de Boer; W Hofhuis; N Reesink-Peters; S Willemsen; I A Boere; I G Schoots; J M J Piek; L N Hofman; J J Beltman; W J van Driel; H M J Werner; A Baalbergen; A M L D van Haaften-de Jong; M Dorman; L Haans; I Nedelcu; P C Ewing-Graham; H J van Beekhuizen
Journal:  Ann Surg Oncol       Date:  2022-05-13       Impact factor: 4.339

Review 2.  Small Non-Coding-RNA in Gynecological Malignancies.

Authors:  Shailendra Kumar Dhar Dwivedi; Geeta Rao; Anindya Dey; Priyabrata Mukherjee; Jonathan D Wren; Resham Bhattacharya
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.